February 7, 2014
A New Tide Approaches
Simeprevir and sofosbuvir both represent a further step in the evolution of more effective, less-toxic HCV treatment options. But they, too, are just the beginning. Numerous direct-acting antiretrovirals are currently moving through the latter stage of the development pipeline, suggesting that the treatment landscape by early 2015 may look as different from the present as the present does from just a few years earlier.
For the notoriously hard-to-treat HCV genotype 1 in particular, Cox states: "It's hard to predict, but right now in advanced testing, there are some combinations that are inteferon-sparing" yet have very high sustained virologic response rates -- and may not even require the use of ribavirin.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|Women and PrEP: The Bridging Role of Local Health Departments|
|Inflammation Persists Despite Very Early HIV Treatment|
|New PrEP Results Exceed HIV Researchers' High Expectations|
|Ben Young: CROI 2015 Data Bolster the Call for Initiative to End HIV/AIDS Epidemic|
|Markers of Immune Exhaustion Predict Post-Treatment Control in HIV Patients|
|Coverage of CROI 2015: The 22nd Conference on Retroviruses and Opportunistic Infections|